CN113683644A - Bis-quinoline iridium complex for treating cisplatin-resistant cancer cells and preparation method and application thereof - Google Patents
Bis-quinoline iridium complex for treating cisplatin-resistant cancer cells and preparation method and application thereof Download PDFInfo
- Publication number
- CN113683644A CN113683644A CN202110988709.7A CN202110988709A CN113683644A CN 113683644 A CN113683644 A CN 113683644A CN 202110988709 A CN202110988709 A CN 202110988709A CN 113683644 A CN113683644 A CN 113683644A
- Authority
- CN
- China
- Prior art keywords
- cisplatin
- iridium complex
- complex
- hydroxyquinoline
- resistant cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 title claims abstract description 40
- 229960004316 cisplatin Drugs 0.000 title claims abstract description 40
- 208000016691 refractory malignant neoplasm Diseases 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- -1 Bis-quinoline iridium Chemical compound 0.000 title claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 28
- 229910052741 iridium Inorganic materials 0.000 claims abstract description 26
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000011259 mixed solution Substances 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 16
- 239000003446 ligand Substances 0.000 claims abstract description 16
- 150000004325 8-hydroxyquinolines Chemical class 0.000 claims abstract description 12
- 150000002503 iridium Chemical class 0.000 claims abstract description 9
- 239000002244 precipitate Substances 0.000 claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 7
- 239000002798 polar solvent Substances 0.000 claims abstract description 7
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 3
- 201000005202 lung cancer Diseases 0.000 claims abstract description 3
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 claims description 7
- GPTXWRGISTZRIO-UHFFFAOYSA-N chlorquinaldol Chemical compound ClC1=CC(Cl)=C(O)C2=NC(C)=CC=C21 GPTXWRGISTZRIO-UHFFFAOYSA-N 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- BNACJQWJZKPAPV-UHFFFAOYSA-N 5,7-dibromo-2-methylquinolin-8-ol Chemical compound BrC1=CC(Br)=C(O)C2=NC(C)=CC=C21 BNACJQWJZKPAPV-UHFFFAOYSA-N 0.000 claims description 3
- ZDASUJMDVPTNTF-UHFFFAOYSA-N 5,7-dibromo-8-quinolinol Chemical compound C1=CN=C2C(O)=C(Br)C=C(Br)C2=C1 ZDASUJMDVPTNTF-UHFFFAOYSA-N 0.000 claims description 3
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 claims description 3
- WDFKMLRRRCGAKS-UHFFFAOYSA-N chloroxine Chemical compound C1=CN=C2C(O)=C(Cl)C=C(Cl)C2=C1 WDFKMLRRRCGAKS-UHFFFAOYSA-N 0.000 claims description 3
- UXZFQZANDVDGMM-UHFFFAOYSA-N iodoquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(I)C2=C1 UXZFQZANDVDGMM-UHFFFAOYSA-N 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 150000001875 compounds Chemical class 0.000 abstract description 11
- 230000005764 inhibitory process Effects 0.000 abstract description 11
- 239000002246 antineoplastic agent Substances 0.000 abstract description 10
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 10
- 229940079593 drug Drugs 0.000 abstract description 9
- 238000001727 in vivo Methods 0.000 abstract description 8
- 230000001093 anti-cancer Effects 0.000 abstract description 7
- 230000005918 in vitro anti-tumor Effects 0.000 abstract description 6
- 206010059866 Drug resistance Diseases 0.000 abstract description 4
- 238000011160 research Methods 0.000 abstract description 3
- 230000001988 toxicity Effects 0.000 abstract description 3
- 231100000419 toxicity Toxicity 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 32
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- FSEXLNMNADBYJU-UHFFFAOYSA-N 2-phenylquinoline Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=N1 FSEXLNMNADBYJU-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 238000011580 nude mouse model Methods 0.000 description 7
- 229940125782 compound 2 Drugs 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 4
- 230000005917 in vivo anti-tumor Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 230000005760 tumorsuppression Effects 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- KHDNHIVJLRCSIR-UHFFFAOYSA-N iridium;quinolin-8-ol Chemical compound [Ir].C1=CN=C2C(O)=CC=CC2=C1 KHDNHIVJLRCSIR-UHFFFAOYSA-N 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 210000001099 axilla Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 150000002397 1-phenylpyrazoles Chemical class 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 238000012984 biological imaging Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000000006 cell growth inhibition assay Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0033—Iridium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a biquinoline iridium complex for treating cisplatin-resistant cancer cells, a preparation method and application thereof, belongs to the field of medicines, and aims to solve the technical problem of drug resistance of cisplatin-type medicines of lung cancer in the prior art, wherein the method specifically comprises the following steps: (1) mixing the iridium dimer [ Ir (2pq)2Cl]2Adding the ligand 8-hydroxyquinoline derivative and a polar solvent to obtain a mixed solution; (2) reacting the obtained mixed solution at 90 ℃ under a sealed condition to obtain a precipitate; (3) and filtering and drying the precipitate to obtain the target complex. Researches find that the complex 2a-2f has good inhibition effect on A549/DDP and SK-OV-3/DDP, and IC thereof50The value is 0.11-1.83 mu M, the in vitro anti-tumor activity of the compound is far greater than that of a 1a-1f ligand and a clinical anti-cancer drug cisplatin, and the compound is normalThe toxicity of HL-7702 cells is very low, which indicates that the cells target tumors and overcome the drug resistance of cisplatin. The research on in vivo anticancer shows that the in vivo anticancer inhibition effect reaches 64.1 percent, and the compound has potential medicinal value and is expected to be used for preparing various antitumor medicaments.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a biquinoline iridium complex for treating cisplatin-resistant cancer cells and a preparation method and application thereof.
Background
Cisplatin drugs are one of the most common chemotherapy drugs in clinical treatment, have obvious curative effect on the treatment of various cancers, and the drug resistance limits the further clinical use of the cisplatin drugs; in addition, the metal iridium complex has long phosphorescence life and large stokes shift, is widely applied to the fields of fluorescent probes, biological imaging, anticancer and the like, and has great prospect as a metal antitumor drug in view of the characteristics of the iridium complex. Therefore, the design of the anticancer iridium complex which targets tumors and overcomes the drug resistance of cisplatin drugs is urgently needed.
Currently, 8-hydroxyquinolinesAnd the 1-phenylpyrazole derivative iridium complex is reported to have better inhibiting effect on cervical cancer HeLa and ovarian cancer cis-platinum drug-resistant cell SK-OV-3/DDP, and is targeted to a mitochondrial membrane of the cervical cancer HeLa (Q. -P. Qin, et al. European Journal of Medicinal Chemistry,2020,192,112192.), but no relevant report is made on synthesizing the metal iridium complex by using 8-hydroxyquinoline derivative and 2-phenylquinoline as a mixed ligand. This study was initiated with the active 8-hydroxyquinoline derivative (1 a-1 f) dimer with 2-phenylquinoline [ Ir (2pq)2Cl]22pq ═ 2-phenylquinoline), and an iridium complex [ Ir (1a) (2pq) thereof was synthesized2](2a)、[Ir(1b)(2pq)2](2b)、[Ir(1c)(2pq)2](2c)、[Ir(1d)(2pq)2](2d)、[Ir(1e)(2pq)2](2e) And [ Ir (1f) (2pq)2](2f) The 8-hydroxyquinoline metal iridium complex for inhibiting the cisplatin resistant cell A549/DDP of the human non-small cell lung cancer cell is researched for the first time, and the in vivo and in vitro anti-tumor activity and the application thereof are researched.
Disclosure of Invention
One of the purposes of the invention is to provide a biquinoline iridium complex for treating cisplatin-resistant cancer cells.
The invention also aims to provide a preparation method of the biquinoline iridium complex for treating the cisplatin-resistant cancer cells.
The invention also aims to provide application of the biquinoline iridium complex for treating the cisplatin-resistant cancer cells in preparation of antitumor drugs.
The first purpose of the invention is realized by the following technical scheme: a bisquinoline iridium complex for treating cisplatin-resistant cancer cells has a chemical structural formula shown as the following formula 1-6:
the second purpose of the invention is realized by the following technical scheme: a preparation method of a biquinoline iridium complex for treating cisplatin-resistant cancer cells comprises the following steps:
(1) mixing the iridium dimer [ Ir (2pq)2Cl]2And ligand 8-hydroxyquinoline derivative (1 a-1 f), adding into a polar solvent to obtain a mixed solution;
(2) reacting the obtained mixed solution at 90 ℃ under a sealed condition to obtain a precipitate;
(3) and filtering and drying the precipitate to obtain the target complex.
As a further improvement, in the step (1), the iridium dimer [ Ir (2pq) ]2Cl]2And 8-hydroxyquinoline derivative (1 a-1 f) ligand at a ratio of 1: 2.
Further, the ligands of the 8-hydroxyquinoline derivative (1 a-1 f) include 5, 7-diiodo-8-hydroxyquinoline (1a), 5, 7-dichloro-8-hydroxyquinoline (1b), 5-chloro-7-iodo-8-hydroxyquinoline (1c), 5, 7-dibromo-8-hydroxyquinoline (1d), 5, 7-dichloro-2-methyl-8-hydroxyquinoline (1e) and 5, 7-dibromo-2-methyl-8-hydroxyquinoline (1 f).
Further, in the step (2), the polar solvent is any one of dichloromethane and methanol or ethanol or a methanol-ethanol mixed solution (in any volume ratio).
Further, the dichloromethane is 0.1-1.5mL, the methanol is 3.5mL, the ethanol is 5.5mL, and the methanol-ethanol mixed solution is 2.5 mL.
Further, in the step (2), the reaction time is 48h, and neither the excessive temperature nor the insufficient temperature has a product or is not a main product.
Further, in the step (3), the drying time is 55 ℃.
The third purpose of the invention is realized by the application of the biquinoline iridium complex in preparing antitumor drugs.
The chemical formula of the bisquinoline iridium complex (2a-2f) is [ Ir (1a) (2pq)2] (2a), [ Ir (1b) (2pq)2] (2b), [ Ir (1c) (2pq)2] (2c), [ Ir (1d) (2pq)2] (2d), [ Ir (1e) (2pq)2] (2e) and [ Ir (1f) (2pq)2] (2f), and the chemical structural formula is shown in FIG. 14.
Dimer of 2-phenylquinoline ([ Ir (2pq) ]according to the present invention2Cl]22pq ═ 2-phenylquinoline) reference synthesis (r.j.watts, et al.j.am. chem.soc.,1984,106,6647-6653.) having the structural formula shown in figure 15.
Advantageous effects
Compared with the prior art, the invention has the advantages that: the invention provides 6 novel bisquinoline iridium complexes [ Ir (1a) (2pq)2](2a)、[Ir(1b)(2pq)2](2b)、[Ir(1c)(2pq)2](2c)、[Ir(1d)(2pq)2](2d)、[Ir(1e)(2pq)2](2e) And [ Ir (1f) (2pq)2](2f) As well as a process for its preparation and use; and the activity and toxicity experiments of the compounds on non-small cell lung cancer cis-platinum resistant strain A549/DDP, human ovarian cancer cis-platinum resistant strain SK-OV-3/DDP and human normal liver HL-7702 cells are considered. Experimental results show that the complex 2a-2f has good inhibition effect on A549/DDP and SK-OV-3/DDP, and IC thereof500.11-1.83 μ M, overcomes the resistance of cisplatin, especially 2e has the best activity to A549/DDP, and IC thereof50The value is 0.11 +/-0.04 mu M, is the anticancer drug of the first 8-hydroxyquinoline iridium complex reaching the nM level, and the in vitro antitumor activity of the anticancer drug is far greater than that of the ligand (1 a-1 f)>50 mu M) and the clinical anticancer drug cisplatin (>50 μ M) and they have little toxicity (IC) to normal cells HL-770250> 50 μ M), suggesting that they target tumors and overcome cisplatin resistance. The research on in vivo anticancer for the first time shows that the in vivo anticancer inhibition effect reaches 64.1 percent, has potential medicinal value and is expected to be used for preparing various antitumor medicaments.
Drawings
FIG. 1 is an electrospray mass spectrum of a complex 2a prepared in example 1 of the present invention;
FIG. 2 is an electrospray mass spectrum of a complex 2b prepared in example 1 of the present invention;
FIG. 3 is an electrospray mass spectrum of complex 2c prepared in example 1 of the present invention;
FIG. 4 is an electrospray mass spectrum of complex 2d prepared in example 1 of the present invention;
FIG. 5 is an electrospray mass spectrum of a complex 2f prepared in example 1 of the present invention;
FIG. 6 is a single crystal structural view of a complex 2c obtained in example 1 of the present invention;
FIG. 7 is a single crystal structural view of a complex 2d obtained in example 1 of the present invention;
FIG. 8 is a NMR chart of complex 2a obtained in example 1 of the present invention;
FIG. 9 is a NMR chart of complex 2b obtained in example 1 of the present invention;
FIG. 10 is a NMR chart of complex 2d obtained in example 1 of the present invention;
FIG. 11 is a NMR chart of complex 2e obtained in example 1 of the present invention;
FIG. 12 is a NMR chart of a complex 2e obtained in example 1 of the present invention;
FIG. 13 is a NMR chart of complex 2f obtained in example 1 of the present invention;
FIG. 14 is a chemical structural formula of bis-quinoline iridium complex (2a-2f) of the present invention;
FIG. 15 is a chemical structural formula of an iridium dimer of the present invention;
FIG. 16 is a scheme showing the synthesis of a complex of the present invention.
Detailed Description
The invention will be further described with reference to specific embodiments shown in the drawings.
Example 1
The preparation method of the biquinoline iridium complex for treating the cisplatin-resistant cancer cells comprises the following steps:
(1) mixing the iridium dimer [ Ir (2pq)2Cl]2And ligand 8-hydroxyquinoline derivative (1 a-1 f), adding into a polar solvent to obtain a mixed solution;
(2) reacting the obtained mixed solution for 48 hours at 90 ℃ under a sealed condition to obtain a precipitate;
(3) and filtering and drying the precipitate to obtain the target complex 2a-2f with the yield of 78.2-91.6%.
In the step (1), the iridium dimer [ Ir (2pq) ]2Cl]2And 8-hydroxyquinoline derivative (1 a-1 f) ligand at a ratio of 1: 2.
The 8-hydroxyquinoline derivative (1 a-1 f) ligands include 5, 7-diiodo-8-hydroxyquinoline (1a), 5, 7-dichloro-8-hydroxyquinoline (1b), 5-chloro-7-iodo-8-hydroxyquinoline (1c), 5, 7-dibromo-8-hydroxyquinoline (1d), 5, 7-dichloro-2-methyl-8-hydroxyquinoline (1e) and 5, 7-dibromo-2-methyl-8-hydroxyquinoline (1 f).
In the step (2), the polar solvent is any one of dichloromethane and methanol or ethanol or a methanol-ethanol mixed solution (in any volume ratio).
0.1-1.5mL of dichloromethane, 3.5mL of methanol, 5.5mL of ethanol and 2.5mL of methanol-ethanol mixed solution.
In the step (3), the drying time was 55 ℃.
The resulting complexes 2a-2f were identified:
(1) the electrospray mass spectrum of complexes 2a-2f is shown in FIGS. 1-5, wherein M is the molecular weight of each complex.
| | | 2c | 2d | 2f | |||
| m/z | 998.0 | 814.05 | 906.00 | 903.95 | 917.70 | ||
| Fragments | [M+H]+ | [M+H]+ | [M+H]+ | [M+H]+ | [M+H]+ |
(2) The single crystal structures of complexes 2c and 2d are shown in FIGS. 6 and 7.
(3) The nuclear magnetic resonance hydrogen and carbon spectra of the complexes 2a-2f are shown in figures 8-13.
Data for compound 2 a: the yield was 78.2%;1H NMR(500MHz,DMSO-d6)δ8.97(d,J＝8.9Hz,1H),8.51(d,J＝8.7Hz,1H),8.46(d,J＝8.5Hz,2H),8.41(d,J＝9.2Hz,1H),8.21(d,J＝7.9Hz,1H),8.08(d,J＝7.9Hz,1H),7.92(dd,J＝16.2,8.9Hz,3H),7.85(d,J＝8.2Hz,1H),7.76(d,J＝4.9Hz,1H),7.51(dd,J＝8.7,5.0Hz,1H),7.46–7.42(m,1H),7.39(d,J＝8.9Hz,1H),7.34(dt,J＝14.8,7.9Hz,2H),7.07(t,J＝7.4Hz,1H),6.99–6.92(m,2H),6.76–6.72(m,1H),6.63(t,J＝7.8Hz,2H),6.13(d,J＝7.6Hz,1H)。
data for compound 2 b: the yield was 91.6%;1H NMR(500MHz,DMSO-d6)δ9.01(d,J＝3.7Hz,1H),8.53(d,J＝8.4Hz,2H),8.47(d,J＝8.5Hz,1H),8.41(d,J＝8.6Hz,1H),8.22(s,1H),8.15(d,J＝8.4Hz,1H),8.10(d,J＝8.5Hz,1H),7.93(d,J＝7.7Hz,1H),7.86(d,J＝9.6Hz,2H),7.77(dd,J＝8.5,4.1Hz,2H),7.54(dd,J＝8.1,4.8Hz,1H),7.43(t,J＝7.4Hz,2H),7.34(d,J＝7.6Hz,1H),7.09–7.05(m,1H),7.00–6.94(m,2H),6.73(d,J＝7.4Hz,1H),6.63(dd,J＝13.8,7.0Hz,2H),6.15(d,J＝7.0Hz,1H)。
data for compound 2 c: the yield was 85.4%.
Data for compound 2 d: the yield was 79.9%;1H NMR(500MHz,DMSO-d6)δ8.98(d,J＝8.5Hz,1H),8.55(d,J＝8.7Hz,1H),8.52(d,J＝9.5Hz,1H),8.47(d,J＝9.3Hz,2H),8.41(d,J＝8.2Hz,1H),8.37(d,J＝9.3Hz,1H),8.21(d,J＝7.9Hz,1H),8.10–8.08(m,1H),7.93(d,J＝7.8Hz,1H),7.84(d,J＝5.6Hz,1H),7.65(s,1H),7.55(dd,J＝7.9,5.6Hz,1H),7.45–7.41(m,2H),7.37–7.32(m,2H),7.08(d,J＝6.0Hz,1H),6.98(d,J＝5.7Hz,1H),6.84–6.81(m,1H),6.76–6.72(m,1H),6.63(d,J＝6.7Hz,1H),6.51–6.47(m,1H),6.15(d,J＝8.1Hz,1H)。
data for compound 2 e: the yield is 90.0%;1H NMR(500MHz,DMSO-d6)δ9.11(d,J＝8.9Hz,1H),8.52–8.46(m,3H),8.40(d,J＝8.9Hz,1H),8.12(d,J＝7.8Hz,1H),8.08(d,J＝8.7Hz,1H),7.99(d,J＝7.6Hz,1H),7.90(d,J＝8.1Hz,2H),7.58(d,J＝9.0Hz,1H),7.41(t,J＝7.4Hz,1H),7.33(q,J＝8.9,8.1Hz,3H),7.27–7.23(m,1H),7.05–7.01(m,1H),6.94(q,J＝7.8Hz,2H),6.64(dt,J＝21.5,7.4Hz,2H),6.57(d,J＝7.6Hz,1H),5.96(d,J＝7.8Hz,1H),2.10(s,3H).13C NMR(126MHz,DMSO)δ171.65,170.31,164.41,160.64,153.30,149.73,147.79,147.56,147.15,146.91,140.13,139.73,138.65,134.80,134.44,132.29,131.11,130.51,130.20,129.62,129.34,128.70,128.09,128.00,127.84,127.62,126.68,126.64,126.55,126.40,125.39,125.26,124.40,122.17,120.87,119.57,117.97,117.60,110.20,40.50,40.33,40.25,40.16,40.00,39.83,39.66,39.50,25.37。
data for compound 2 f: the yield was 78.6%;1H NMR(500MHz,DMSO-d6)δ9.10(d,J＝8.9Hz,1H),8.53–8.46(m,3H),8.40(d,J＝9.0Hz,1H),8.13(d,J＝7.8Hz,1H),8.02(d,J＝8.5Hz,1H),7.99(d,J＝7.8Hz,1H),7.91(d,J＝7.6Hz,2H),7.55(d,J＝7.6Hz,2H),7.43–7.39(m,1H),7.33(t,J＝8.0Hz,2H),7.28–7.24(m,1H),7.04–7.00(m,1H),6.97–6.91(m,2H),6.68–6.65(m,1H),6.62(t,J＝7.6Hz,1H),6.58(d,J＝7.8Hz,1H),5.95(d,J＝7.6Hz,1H),2.10(s,3H)。
(4) the results of elemental analysis are shown in Table 1.
Table 1 results of elemental analysis of complexes 2a to 2f in examples
Therefore, the target product of the obtained red-brown bulk crystal or red-brown powder can be determined to be the complex 2a-2f, and the structural formula of the complex is shown in figure 14.
Example 2
Different from example 1, in the step (2), the solvent is 0.5mL of dichloromethane and 5.5mL of ethanol which are added dropwise, and the yield is 79.9-90.0%.
Example 3
Different from example 1 in that the solvent added dropwise in the step (2) was a mixed solution of 1.5mL of dichloromethane and 2.5mL of methanol-ethanol, and the yield was 81.2-91.1%.
In order to fully illustrate the application of the biquinoline iridium complex for treating the cisplatin-resistant cancer cells in pharmacy, the applicant performs in-vitro and in-vivo anti-tumor activity experiments on the complex.
Experiment on proliferation inhibition activity of iridium anti-cancer complex on various human tumor cell strains
1. Cell lines and cell cultures
The experiment selects 3 cell strains such as a non-small cell lung cancer cisplatin-resistant strain A549/DDP, a human ovarian cancer cisplatin-resistant strain SK-OV-3/DDP, a human normal liver HL-7702 cell and the like.
All human cell lines were cultured in RPMI-1640 medium containing 100U/mL penicillin, 10 wt% calf blood and 100U/mL streptomycin, and cultured in an incubator containing 5% CO2 at 37 ℃.
2. Preparation of test Compounds
The purity of the ligand and the complex used needs to be more than or equal to 95 percent, the DMSO stock solution of the ligand and the complex is diluted into a final solution of 20 mu mol/L (the final concentration of DMSO is less than or equal to 1 percent) by using a physiological buffer solution, and the degree of inhibition of the growth of normal cells or selected tumor cells by each compound under the concentration is tested.
3. Cell growth inhibition assay (MTT method)
(1) Taking normal cells or tumor cells in a logarithmic growth phase, digesting the cells or tumor cells by trypsin, preparing a cell suspension with the concentration of 5000/mL by using a culture solution containing 10% calf serum, inoculating 190 mu L of the cell suspension into a 96-hole culture plate, and enabling the density of cells to be detected to reach 1000-10000 holes (the edge holes are filled with sterile PBS);
(2)5％CO2incubating for 24h at 37 ℃ until a cell monolayer is paved on the bottom of each well, adding 10 mu L of medicine with a certain concentration gradient into each well, and arranging 4 compound wells in each concentration gradient;
(3)5％CO2incubating for 48h at 37 ℃, and observing under an inverted microscope;
(4) add 10. mu.L of MTT solution (5mg/mL PBS, i.e., 0.5% MTT) to each well and continue culturing for 4 h;
(5) terminating the culture, carefully removing the culture solution in the wells, adding 150 μ L of DMSO into each well to sufficiently dissolve formazan precipitate, mixing uniformly with an oscillator, and measuring the optical density of each well with a microplate reader at a wavelength of 570nm and a reference wavelength of 450 nm;
(6) simultaneously, a zero setting hole (culture medium, MTT, DMSO) and a control hole (cells, culture solution, MTT, a drug dissolving medium with the same concentration, DMSO) are arranged.
(7) The number of living cells was judged from the measured optical density values (OD values), and the larger the OD value, the stronger the cell activity. Using the formula:
calculating the inhibition rate of each compound on the growth of the selected cells, and calculating the IC of each tested compound on each selected cell strain by a Bliss method50The value is obtained. The results are shown in table 2 below.
TABLE 2 IC of Compounds on various cell lines50Value (μ M)
Slave IC50The activity screening result shows that the complex 2a-2f has good inhibition effect on A549/DDP and SK-OV-3/DDPIC thereof500.11-1.83 μ M, overcomes the resistance of cisplatin, especially 2e has the best activity to A549/DDP, and IC thereof50The value is 0.11 +/-0.04 mu M, is the anticancer drug of the first 8-hydroxyquinoline iridium complex reaching the nM level, and the in vitro antitumor activity of the anticancer drug is far greater than that of the ligand (1 a-1 f)>50 mu M) and the clinical anticancer drug cisplatin (>50 μ M) and they have little toxicity (IC) to normal cells HL-770250> 50 μ M), suggesting that they target tumors and overcome cisplatin resistance. It is worth emphasizing that the complex 2a-2f is the first proven 8-hydroxyquinoline iridium complex which has obvious inhibition effect on the cisplatin-resistant strain lung cancer A549/DDP, has potential medicinal value and is expected to be used for preparing various antitumor medicaments.
Second, in vivo tumor suppression experiment of tumor-bearing nude mice
(1) Animal requirements:
strain: BALB/c-nu; grade: an SPF level; the week age is as follows: 5-6 w; weight: 18-20 g; sex: male;
(2) animal sources:
supplied by Changzhou Kavens laboratory animals Ltd (laboratory animal production license: SCXK (threo) 2016-.
(3) Site of animal experiment:
license for use of experimental animal: SYXK (threo) 2017-0040.
(4) The requirements of the breeding environment are as follows:
SPF class, IVC independent ventilation system; keeping constant temperature (26 +/-2 ℃) and humidity (40-70%), and turning on and off the lamp for 12h respectively.
(5) Feed:
SPF mouse breeding feed is selected and purchased from Australian cooperative feed Co., Ltd, Beijing.
(6) Main reagents and instruments used for the experiments:
reagent: DMSO, 0.9% of normal saline, 75% of medical alcohol and 4% of paraformaldehyde; the apparatus is as follows: surgical scissors, forceps, a trocar and an electronic vernier caliper.
(7) Basic procedure and operation of the experiment:
(ii) cell culture
For experimental cell lines and cell cultures, please refer to the above section.
② preparation of lotus A549/DDP model
Cancer cells in logarithmic growth phase were collected and prepared into a suspension of 5X 107 viable cells/mL in serum-free medium. 0.2mL of suspension containing about 1X 107 viable cells was extracted with a 1.0mL syringe and then inoculated subcutaneously into the right axilla of nude mice until the subcutaneous tumor grew to about 1cm3In time, the tumor source was generated as a subcutaneous tumor model and passaged on nude mice. Passing tumor on nude mouse for 4 generations until its growth is stable, selecting tumor-bearing mouse with vigorous tumor growth and no rupture, killing cervical vertebra dislocation, sterilizing animal skin with 75% medical alcohol, dissecting tissue block, removing necrotic part, and cutting tumor tissue into 1.5mm3The left and right small blocks are inoculated under the skin of the right axilla of the nude mouse by a trocar. Measuring the tumor diameter of the transplanted tumor by using an electronic vernier caliper until the tumor volume grows to 100-3At time, animals were randomly grouped.
(iii) drug efficacy experiment
Nude tumor mice were randomly divided into vehicle group, drug-added group and cisplatin positive control group, with 7 animals per group. The intraperitoneal injection administration is started on the grouping day, the compound is administered every two days, and the cisplatin is administered every other day. The tumor diameter was measured every three days with an electronic vernier caliper, and the body weight was measured. And (3) killing the cervical vertebra at dislocation on the 15 th day, dissecting tumors, weighing, photographing and calculating the tumor inhibition rate.
Tumor volume calculation formula: v ═ a × b2A is a long diameter, and b is a short diameter;
relative tumor volume RTV ═ Vt/V0In which V istVolume at each measurement, V0Volume when grouped;
relative tumor increment rate T/C ═ TRTV/CRTV)×100％；
The tumor growth inhibition ratio (%) (mean tumor weight in vehicle group-mean tumor weight in treatment group)/mean tumor weight in vehicle group × 100%.
As seen from the results of the in vivo tumor suppression experiment shown in the above Table 3, after 15 days of administration, the complex 2e has a better inhibitory effect on tumor nude mice, and the tumor suppression rate is as high as 64.1%, which far exceeds the tumor suppression rate (33.1%) of clinical drug cisplatin (the cisplatin data is from M. -X. tan, et al. Dalton trans.,2020,49, 1613-one 1619.). In conclusion, the iridium complex shows good in vivo and in vitro anti-tumor activity, has good potential medicinal value, and is expected to be used for preparing various anti-tumor medicaments.
TABLE 3 in vivo anti-tumor results of Complex 2e on A549/DDP-bearing nude mice
The above is only a preferred embodiment of the present invention, and it should be noted that it is obvious to those skilled in the art that several variations and modifications can be made without departing from the structure of the present invention, which will not affect the effect and practicality of the present invention.
Claims (10)
1. A biquinoline iridium complex for treating cisplatin-resistant cancer cells is characterized in that the chemical structural formula is as follows:
2. the preparation method of the biquinoline iridium complex for treating cisplatin-resistant cancer cells as claimed in claim 1, comprising the following steps:
(1) mixing the iridium dimer [ Ir (2pq)2Cl]2And ligand 8-hydroxyquinoline derivative (1 a-1 f) into a polar solvent to obtain a mixed solution;
(2) reacting the obtained mixed solution at 90 ℃ under a sealed condition to obtain a precipitate;
(3) and filtering and drying the precipitate to obtain the target complex.
3. The bisquine for treating cisplatin-resistant cancer cell as claimed in claim 2A process for producing an iridium complex, characterized in that in the step (1), the iridium dimer [ Ir (2pq) ]2Cl]2And ligand 8-hydroxyquinoline derivative (1 a-1 f) in a mass ratio of 1: 2.
4. The method for preparing a bis-quinoline iridium complex for treating cisplatin-resistant cancer cells as claimed in any of claims 2 or 3, wherein the ligand 8-hydroxyquinoline derivative (1 a-1 f) is 5, 7-diiodo-8-hydroxyquinoline (1a), 5, 7-dichloro-8-hydroxyquinoline (1b), 5-chloro-7-iodo-8-hydroxyquinoline (1c), 5, 7-dibromo-8-hydroxyquinoline (1d), 5, 7-dichloro-2-methyl-8-hydroxyquinoline (1e) or 5, 7-dibromo-2-methyl-8-hydroxyquinoline (1 f).
5. The preparation method of the bis-quinoline iridium complex for treating cisplatin-resistant cancer cells as claimed in claim 2, wherein the polar solvent is a mixed solution of dichloromethane and methanol or a mixed solution of dichloromethane and ethanol or a mixed solution of dichloromethane and methanol-ethanol.
6. The preparation method of the bisquinoline iridium complex for treating cisplatin-resistant cancer cell as claimed in claim 5, wherein the dichloromethane is 0.1-1.5mL, the methanol is 3.5mL, the ethanol is 5.5mL, and the methanol-ethanol mixed solution is 2.5 mL.
7. The preparation method of the bis-quinoline iridium complex for treating cisplatin-resistant cancer cells as claimed in claim 2, wherein in the step (2), the reaction time is 48 h.
8. The preparation method of the bis-quinoline iridium complex for treating cisplatin-resistant cancer cells as claimed in claim 2, wherein in the step (3), the drying time is 55 ℃.
9. The use of the biquinoline iridium complex for treating cisplatin-resistant cancer cells as claimed in claim 1 in the preparation of an antitumor medicament.
10. The use of the biquinoline iridium complex for the treatment of cisplatin-resistant cancer cells as claimed in claim 1 in the preparation of an antitumor medicament, wherein said tumors comprise lung cancer and liver cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110988709.7A CN113683644B (en) | 2021-08-26 | 2021-08-26 | Bis-quinoline iridium complex for treating cisplatin-resistant cancer cells and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110988709.7A CN113683644B (en) | 2021-08-26 | 2021-08-26 | Bis-quinoline iridium complex for treating cisplatin-resistant cancer cells and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113683644A true CN113683644A (en) | 2021-11-23 |
| CN113683644B CN113683644B (en) | 2022-05-20 |
Family
ID=78583132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110988709.7A Active CN113683644B (en) | 2021-08-26 | 2021-08-26 | Bis-quinoline iridium complex for treating cisplatin-resistant cancer cells and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113683644B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114057778A (en) * | 2021-11-22 | 2022-02-18 | 广东石油化工学院 | High-anticancer-activity complex based on dimethyl pyridylamine-zinc, derivative and preparation method thereof |
| CN114409707A (en) * | 2022-01-21 | 2022-04-29 | 玉林师范学院 | 8-hydroxyquinoline-N-manganese oxide complex and synthesis method and application thereof |
Citations (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120165370A1 (en) * | 2007-08-21 | 2012-06-28 | Tang Johnny Cheuk-On | Quinoline derivatives as anti-cancer agents |
| US20130065864A1 (en) * | 2010-05-22 | 2013-03-14 | University Of Warwick | Novel iridium/rhodium anti-cancer compounds |
| CN104163834A (en) * | 2013-05-17 | 2014-11-26 | 复旦大学 | Iridium complex, and preparation method and pharmaceutical application thereof |
| CN106939025A (en) * | 2016-12-26 | 2017-07-11 | 中山大学 | One class inducing cell rises complex of iridium for dying and preparation method thereof and antitumor application thereof |
| CN110172075A (en) * | 2019-06-21 | 2019-08-27 | 玉林师范学院 | A kind of novel coumarin-quinoline-platinum (II) complex and its synthetic method and application |
| CN110950914A (en) * | 2019-12-23 | 2020-04-03 | 广西师范大学 | Iridium complex and synthesis method and application thereof |
| CN111039990A (en) * | 2019-12-23 | 2020-04-21 | 广西师范大学 | Low-toxicity iridium complex and synthesis method and application thereof |
| CN111072727A (en) * | 2019-12-23 | 2020-04-28 | 广西师范大学 | Iridium complex constructed based on 8-hydroxyquinoline derivative and 2-phenylpyridine iridium dimer as well as synthetic method and application thereof |
| CN111960998A (en) * | 2020-08-03 | 2020-11-20 | 江苏亚虹医药科技有限公司 | Nitroxoline derivatives, preparation method and application thereof |
| CN111961084A (en) * | 2019-05-20 | 2020-11-20 | 玉林师范学院 | Lung cancer cell inhibitor and preparation method thereof |
| CN112679549A (en) * | 2020-12-24 | 2021-04-20 | 玉林师范学院 | 8-hydroxyquinoline derivative iridium (III) complex and preparation method and application thereof |
| CN113024584A (en) * | 2021-03-24 | 2021-06-25 | 玉林师范学院 | 8-hydroxyquinoline complex for treating lung cancer and preparation method thereof |
-
2021
- 2021-08-26 CN CN202110988709.7A patent/CN113683644B/en active Active
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120165370A1 (en) * | 2007-08-21 | 2012-06-28 | Tang Johnny Cheuk-On | Quinoline derivatives as anti-cancer agents |
| US20130065864A1 (en) * | 2010-05-22 | 2013-03-14 | University Of Warwick | Novel iridium/rhodium anti-cancer compounds |
| CN104163834A (en) * | 2013-05-17 | 2014-11-26 | 复旦大学 | Iridium complex, and preparation method and pharmaceutical application thereof |
| CN106939025A (en) * | 2016-12-26 | 2017-07-11 | 中山大学 | One class inducing cell rises complex of iridium for dying and preparation method thereof and antitumor application thereof |
| CN111961084A (en) * | 2019-05-20 | 2020-11-20 | 玉林师范学院 | Lung cancer cell inhibitor and preparation method thereof |
| CN110172075A (en) * | 2019-06-21 | 2019-08-27 | 玉林师范学院 | A kind of novel coumarin-quinoline-platinum (II) complex and its synthetic method and application |
| CN110950914A (en) * | 2019-12-23 | 2020-04-03 | 广西师范大学 | Iridium complex and synthesis method and application thereof |
| CN111039990A (en) * | 2019-12-23 | 2020-04-21 | 广西师范大学 | Low-toxicity iridium complex and synthesis method and application thereof |
| CN111072727A (en) * | 2019-12-23 | 2020-04-28 | 广西师范大学 | Iridium complex constructed based on 8-hydroxyquinoline derivative and 2-phenylpyridine iridium dimer as well as synthetic method and application thereof |
| CN113072591A (en) * | 2019-12-23 | 2021-07-06 | 广西师范大学 | Iridium complex and synthesis method and application thereof |
| CN111960998A (en) * | 2020-08-03 | 2020-11-20 | 江苏亚虹医药科技有限公司 | Nitroxoline derivatives, preparation method and application thereof |
| CN112679549A (en) * | 2020-12-24 | 2021-04-20 | 玉林师范学院 | 8-hydroxyquinoline derivative iridium (III) complex and preparation method and application thereof |
| CN113024584A (en) * | 2021-03-24 | 2021-06-25 | 玉林师范学院 | 8-hydroxyquinoline complex for treating lung cancer and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| SALIH ÖKTEN 等: "Quinoline-based promising anticancer and antibacterial agents, and some metabolic enzyme inhibitors", 《ARCHIV DER PHARMAZIE》 * |
| YANG YAN 等: "Synthesis and biological evaluation of mixed-ligand cyclometalated iridium(iii)–quinoline complexes", 《DALTON TRANSACTIONS》 * |
| ZHI-LIN CHEN 等: "Cyclometalated iridium(III)-5-bromo-8-quinolinol complexes as mitochondria-targeted anticancer agents", 《INORGANIC CHEMISTRY COMMUNICATIONS》 * |
| 覃姣兰 等: "8-羟基喹啉及其衍生物金属配合物抗肿瘤和抗菌活性研究进展", 《中国科学》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114057778A (en) * | 2021-11-22 | 2022-02-18 | 广东石油化工学院 | High-anticancer-activity complex based on dimethyl pyridylamine-zinc, derivative and preparation method thereof |
| CN114057778B (en) * | 2021-11-22 | 2023-05-12 | 广东石油化工学院 | High anticancer active complex based on dimethyl pyridine amine-zinc, derivative and preparation method thereof |
| CN114409707A (en) * | 2022-01-21 | 2022-04-29 | 玉林师范学院 | 8-hydroxyquinoline-N-manganese oxide complex and synthesis method and application thereof |
| CN114409707B (en) * | 2022-01-21 | 2023-10-10 | 玉林师范学院 | 8-hydroxyquinoline-N-oxide manganese complex and synthetic method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113683644B (en) | 2022-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113683644B (en) | Bis-quinoline iridium complex for treating cisplatin-resistant cancer cells and preparation method and application thereof | |
| CN110054652B (en) | Jatrorrhizine platinum (II) complex and synthesis method and application thereof | |
| CN108774270B (en) | Sorafenib antitumor platinum (II) complex targeting drug-resistant cells of human lung cancer and preparation method and application thereof | |
| CN111187303B (en) | Platinum (II) complex with high antitumor activity of cryptolepine, and synthetic method and application thereof | |
| CN113527370B (en) | Quinoline iridium complex targeting lung cancer cisplatin drug-resistant cells and synthesis method and application thereof | |
| CN111039990B (en) | Low-toxicity iridium complex and synthesis method and application thereof | |
| CN112961188B (en) | Tetravalent platinum prodrug platinum benzydate, preparation thereof, preparation method and application | |
| CN109810148B (en) | Binuclear terpyridyl platinum (II) complex and preparation method and application thereof | |
| CN108659051B (en) | High-activity coumarin-platinum (II) complex targeting ovarian cancer and synthesis method and application thereof | |
| CN110950914A (en) | Iridium complex and synthesis method and application thereof | |
| CN111205311A (en) | Novel high-antitumor-activity white leaf vine zinc (II) complex and synthesis method and application thereof | |
| CN111153916A (en) | White leaf vine zinc (II) complex and synthesis method and application thereof | |
| CN111253418A (en) | Novel white leaf vine zinc (II) complex and synthesis method and application thereof | |
| CN114573598B (en) | White She Tengxin (II) complex with high in-vivo and in-vitro activity and synthesis method and application thereof | |
| CN110950915B (en) | Novel rhein-platinum (IV) precursor anticancer complex and synthesis method and application thereof | |
| CN110054651B (en) | Targeted human bladder cancer jatrorrhizine platinum (II) complex and synthesis method and application thereof | |
| CN114539294B (en) | Cisplatin-resistant cell white rattan-phenanthrene Luo Linxin (II) complex for targeting human lung adenocarcinoma, synthesis method and application thereof | |
| CN108997436B (en) | Rueglini antitumor platinum (II) complex and preparation method and application thereof | |
| CN114057778B (en) | High anticancer active complex based on dimethyl pyridine amine-zinc, derivative and preparation method thereof | |
| CN114106020B (en) | Pyrimidine Schiff base o-phenanthroline-copper-based high anticancer active complex and preparation method thereof | |
| CN115850347A (en) | Lung cancer cell inhibitor and preparation method and application thereof | |
| CN113929720B (en) | Complex targeting human lung cancer drug-resistant cells and preparation method thereof | |
| CN108456231B (en) | Bis-halo coumarin-platinum (II) complex and synthesis method and application thereof | |
| CN117551137A (en) | 2,2':6', 2' -terpyridine derivative dinuclear platinum complex and synthetic method and application thereof | |
| CN115385940B (en) | Zinc (II) complex of sinomenine and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20211123 Assignee: Guangxi Kangjian AoXin Biomedical Technology Co.,Ltd. Assignor: Yulin Normal University Contract record no.: X2022450000331 Denomination of invention: A bis quinoline iridium complex for cisplatin resistant cancer cells and its preparation and application Granted publication date: 20220520 License type: Common License Record date: 20221217 |